IU Health Arnett Clinical Research

Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy.

Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.

IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.

"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye

Overview

Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy.

Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.

IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.

"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye

Treatment/ Interventional Trials

Breast Cancer

Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

IUSCC-J13104: A randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer

Lung Cancer

Mirati 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy


Solid Tumor Malignancies with FGFR Mutations

Incyte INCB 54828-207: A Phase 2, Open-Label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Non-Treatment/Observational/Blood Sample Collection Trials

Breast cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Lung Cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-093: Collection of fresh blood from PD1/PDL1 treatment naïve NSCLC cancer patients.

Prostate cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-118: Collection of EDTA plasma from metastatic castrate resistant prostate cancer (mCRPC) patients.

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Non-Hodgkin’s Lymphoma

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Urothelial Carcinoma

AstraZeneca D419BR00008: PREVAIL - A prospective, Non-Interventional Study to Assess the Prevalence of PDL1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma

Colorectal and Gastrointestinal Cancer

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Ovarian Cancer

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Current Trials

Treatment/ Interventional Trials

Breast Cancer

Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

IUSCC-J13104: A randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer

Lung Cancer

Mirati 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy


Solid Tumor Malignancies with FGFR Mutations

Incyte INCB 54828-207: A Phase 2, Open-Label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Non-Treatment/Observational/Blood Sample Collection Trials

Breast cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Lung Cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-093: Collection of fresh blood from PD1/PDL1 treatment naïve NSCLC cancer patients.

Prostate cancer

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Dx Biosamples DxB-118: Collection of EDTA plasma from metastatic castrate resistant prostate cancer (mCRPC) patients.

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Non-Hodgkin’s Lymphoma

Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Urothelial Carcinoma

AstraZeneca D419BR00008: PREVAIL - A prospective, Non-Interventional Study to Assess the Prevalence of PDL1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma

Colorectal and Gastrointestinal Cancer

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

Ovarian Cancer

Dx Biosamples DxB-120: Collection of fresh blood from Stage IV cancer patients

For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:

Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email

Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email

Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email

Contact

For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:

Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email

Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email

Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email